Self-sampling to increase participation in cervical cancer screening: An RCT comparing home mailing, distribution in pharmacies, and recall letter

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 667-675

  Giorgi Rossi, P ^a,b   Fortunato, C ^c   Barbarino, P ^d   Boveri, S ^e   Caroli, S ^a,b   Del Mistro, A ^f   Ferro, A ^g   Giammaria, C ^h   Manfredi, M ⁱ   Moretto, T ^j   Pasquini, A ⁱ   Sideri, M ^e   Tufi, M C ^d   Cogo, C ^k   Altobelli, E ^c  

^a PATHOLOGY UNIT   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UOC Screening e Prevenzione ASL Roma G   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g Dipartimento di Prevenzione Azienda ULSS 17   (Italy)

^h Screening Oncologici Regionali Ospedale Cardarelli   (Italy)

ⁱ Azienda USL di Bologna   (Italy)

^j Dipartimento di Prevenzione Azienda ULSS 7 Pieve di Soligo Conegliano   (Italy)

^k Registro Tumori Veneto   (Italy)

more..

Author keywords

cervical cancer; HPV test; randomised controlled trial; screening; self sampling

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; CERVICOVAGINAL SELF-SAMPLING DEVICE; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; HOME; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPANICOLAOU TEST; PHARMACY; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SELF CARE; STANDARD; UTERINE CERVIX CANCER; WART VIRUS; CLINICAL TRIAL; DEVICES; EARLY DIAGNOSIS; INFORMATION PROCESSING; ITALY; LABORATORY DIAGNOSIS; MIDDLE AGED; PATIENT PARTICIPATION; POSTAL MAIL; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; WRITING;

ADULT; CORRESPONDENCE AS TOPIC; DATA COLLECTION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; ITALY; MIDDLE AGED; PATIENT PARTICIPATION; PHARMACIES; POSTAL SERVICE; SELF CARE; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84923624262     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.11     Document Type: Article

References (52)

1. Anttila A. (2007). Cervical cancer screening is effective - the Finnish experience. Entre Nous (WHO Regional Office, Copenhagen) 64: 26-28
2. ArbynM, Castellsagué X, De Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol 22: 2675-2686
3. Arbyn M, Rebolj M, De Kok IM, Becker N, O'Reilly M, Andrae B. (2009). The challenges for organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 45: 2671-2678
4. Arbyn M, Ronco G, Anttila A, CJLM Meijer, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. (2012). Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5): F88-F99
5. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A. (2014). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 15: 172-183
6. Bertozzi N, Carrozzi G, Sampaolo L, Bolognesi L, Finarelli AC, Angelini P, Mignai R, Sacchi AR, Nieddu A, Bulla C, Ferrari AM, Pandolfi P, Perlangeli V, Collina N, De Lisio S, Blundo G, Stefanelli I, De Togni A, Silvi G, Raineri C, Mingozzi O, Sardonini L, Vitali P, Morri M. (2013). I dati della sorveglianza PASSI sulla diagnosi precoce dei tumori del collo dell'utero: confronto fra Emilia-Romagna e Italia (2010-11). In I programmi di screening oncologici. Regione Emilia-Romagna Collana Contributi 74: 84-89
7. Blackwell DL, Martinez ME, Gentleman JF. (2008). Women's Compliance with Public Health Guidelines for Mammograms and Pap tests in Canada and the United States: an analysis of data from the Joint Canada/United States Survey of Health. Women's Health Issues 18: 85-99
8. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. (2006). Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 119: 2372-2375
9. Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, De Kuyper-de Ridder GM, Meijer CJ, Snijders PJ, Heideman DA, IntHout J, van Kemenade FJ, Melchers WJ, Bekkers RL. (2015). Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int J Cancer 136: 646-655
10. Bouvard V, Baan R, Straif K, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Gogliano V. on behalf of the WHO IARC in Cancer Monograph working group. (2009). A review of human carcinogens-part B: biological agents. Lancet Oncol 10: 321-322
11. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van Kemenade F, Frasen Daalmeijer N, Hesselink AT, Berkhof J, Snijders PJ. (2006). High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel selfsampling device to a conventional endocervical brush. J Clin Microbiol 44: 2518-2523
12. Budge M, Halford J, Haran M, Mein J, Wright G. (2005). Comparison of a self-administered tampon ThinPrep test with conventional pap smears for cervical cytology. Aust N Z J Obstet Gynaecol 45: 215-219
13. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. (2007). Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772
14. Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P, Guasticchi G, Giorgi Rossi P. Methods to increase participation Working Group. (2013). Methods to increase participation in organised screening programs: a systematic review. BMC Public Health 13: 464
15. Confortini M, Giorgi Rossi P, Barbarino P, Passarelli AM, Orzella L, Tufi MC. (2010). Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. J Med Screen 17: 79-86
16. Darlin L, Borgfeldt C, Forslund O, Hénic E, Hortlund M, Dillner J, Kannisto P. (2013). Comparison of use of vaginalHPVself-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J Clin Virol 58(1): 155-160
17. Del Mistro A, Frayle H, Ferro A, Callegaro S, Del Sole A, Stomeo A, Cirillo E, Fedato C, Pagni S, Barzon L, Zorzi M. Veneto HPV-screening Working Group. (2014). Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. J Med Screen 21: 30-37
18. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, De Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T. Joint European Cohort Study. (2008). Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 13(337): a1754
19. Garcia F, Barker B, Santos C, Brown EM, Nun'o T, Giuliano A, Davis J. (2003). Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 102: 266-272
20. Giorgi Rossi P, Caroli S, Mancini S, Sassoli De' Bianchi P, Finarelli AC, Naldoni C, Bucchi L, Falcini F. the Emilia-Romagna cervical cancer screening and pathology registry group. (2014). Screening history of cervical cancers in Emilia-Romagna, Italy: defining priorities to improve cervical cancer screening. Eur J Cancer Prev. published online on 2014 April 30. PubMed PMID: 24787379
21. Giorgi Rossi P, Chini F, Borgia P, Guasticchi G, Carozzi FM, Confortini M, Angeloni C, Buzzoni C, Buonauguro FM; Gruppo di lavoro HPV Prevalenza. (2012). Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy. Epidemiol Prev 36(2): 108-119
22. Giorgi Rossi P, Grazzini G, Anti M, Baiocchi D, Barca A, Bellardini P, Brezzi S, Camilloni L, Falini P, Maccallini V, Mantellini P, Romeo D, Rubeca T, Venditti MA (2011a) Direct mailing of faecal occult blood tests for colorectal cancer screening: a randomized population study from Central Italy. J Med Screen 18: 121-127
23. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, Di Pierro C, Grazzini G, Angeloni C, Capparucci P, Pellegrini A, Schiboni ML, Sperati A, Confortini M, Bellanova C, D'Addetta A, Mania E, Visioli CB, Sereno E, Carozzi F. Self-Sampling Study Working Group (2011b) the Effect of Self-sampled HPV Testing on Participation to Cervical Cancer Screening in Italy: A Randomised Controlled Trial (ISRCTN96071600). Br J Cancer 104: 248-254
24. Gök M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, Voorhorst F, Beliën JA, Babovic M, Snijders PJ, Meijer CJ. (2010). HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340: c1040
25. Gök M, Heideman DA, van Kemenade FJ, De Vries AL, Berkhof J, Rozendaal L, Beliën JA, Overbeek L, Babović M, Snijders PJ, Meijer CJ. (2012). Offering self-sampling for human papillomavirus testing to nonattendees of the cervical screening programme: characteristics of the responders. Eur J Cancer 48: 1799-1808
26. IARC Working Group on the Evaluation of Cancer Preventive Strategies Cervix Cancer Screening. (2005). IARC Handbooks of Cancer Prevention No. 10. Lyon: IARC
27. Ingemann-Hansen O, Lidang M, Niemann I, Dinesen J, Baandrup U, Svanholm H, Petersen L. (2008). Screening history of women with cervical cancer: a 6-year study in Aarhus, Denmark. Br J Cancer 98: 1292-1294
28. Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, Yood MU, Gilbert J, Taplin SH. (2005). Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 97: 675-683
29. Lönnberg S, Anttila A, Kotaniemi-Talonen L, Kujari H, Melkko J, Granroth G, Vornanen M, Pietiläinen T, Sankila A, Arola J, Luostarinen T, Nieminen P. (2010). Low proportion of false-negative smears in the Finnish program for cervical cancer screening. Cancer Epidemiol Biomarkers Prev 19: 381-387
30. Lönnberg S, Anttila A, Luostarinen T, Nieminen P. (2012). Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 21: 1354-1361
31. Lönnberg S, Nieminen P, Luostarinen T, Anttila A. (2013). Mortality audit of the Finnish cervical cancer screening program. Int J Cancer 132: 2134-2140
32. Morrell S, Taylor R, Wain G. (2005). A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003. J Med Screen 12: 190-196
33. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J. (2007). Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357: 1589-1597
34. Nieminen P, Kallio M, Anttila A, Hakama M. (1999). Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 83: 55-58
35. Piana L, Leandri FX, Le Retraite L, Heid P, Tamalet C, Sancho-Garnier H. (2011). [HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône]. Bull Cancer 98: 723-731
36. Pippa G, Ferrara M, Valle S, Diego B, Alessandra B, Apuzzo M, Bazuro ME, Tammaro G, Federici A. (2009). [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies]. Recenti Prog Med 100: 348-351
37. Quinn M, Babb P, Jones J, Allen E. (1999). Effect of screening on incidence and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318: 904-908
38. Racey CS, Withrow DR, Gesink D. (2013). Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and metaanalysis. Can J Public Health 104: e159-e166
39. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, CJLM Meijer. the International HPV Screening Working Group. (2014). Efficacy of HPV-based screening for preventing invasive cervical cancer: follow-up of European randomised controlled trials. Lancet 383: 524-532
40. Ronco G, Giorgi Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J. (2010). Efficacy of Human Papillomavirus testing on the subsequent detection of cervical invasive and intraepithelial neoplasia: results from a randomised controlled trial. Lancet Oncol 11: 249-257
41. Ronco G, Pilutti S, Patriarca S, Montanari G, Ghiringhello B, Volante R, Giordano L, Zanetti R, Mancini E, Segnan N. Turin Cervical Screening Working Group. (2005). Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. Br J Cancer 93: 376-378
42. Sancho-Garnier H, Tamalet C, Halfon P, Leandri F, Le Retraite L, Djoufelkit K, Heid P, Davies P, Piana L. (2013). HPV self-sampling or the pap-smear: a randomized study among cervical screening non-attenders from lower socio-economic groups in France. Int J Cancer 133: 2681-2687
43. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DA, Meijer CJ. (2013). High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 132: 2223-2236
44. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. (2000). Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 88: 2283-2289
45. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, Lyons D, Walker J, Christison J, Frater A, Waller J. (2011). HPV selfsampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer 104: 915-920
46. Viikki M, Pukkala E, Hakama M. (1999). Risk of cervical cancer after a negative Pap smear. J Med Screen 6: 103-107
47. Virtanen A, Anttila A, Luostarinen T, Nieminen P (2011a) Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer 128: 2681-2687
48. Virtanen A, Nieminen P, Luostarinen T, Anttila A (2011b) Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 20: 1960-1969
49. WHO. (2006). Comprehensive Cervical Cancer Control. A guide to essential practice. WHO: Geneva
50. Wikström I, Lindell M, Sanner K, Wilander E. (2011). Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 105: 337-339
51. Zorzi M, Del Mistro A, Farruggio A, de' Bartolomeis L, Frayle Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A. (2013). Use of high-risk Human Papillomavirus DNA test as primary test in a cervical cancer screening programme: a population-based cohort study. BJOG 120: 1260-1267
52. Zucchetto A, Ronco G, Giorgi Rossi P, Zappa M, Ferretti S, Franzo A, Falcini F, Visioli CB, Zanetti R, Biavati P, La Rosa F, Baracco S, Federico M, Campari C, De Togni A, Piffer S, Pannozzo F, Fusco M, Michiara M, Castaing M, Seghini P, Tisano F, Serraino D. IMPATTO CERVICEWorking Group. (2013). Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Prev Med 57: 220-226